Steve Bryson is a science writer for Rett Syndrome News with a PhD in biochemistry. He covers the latest news and information on a variety of Rett syndrome topics.| Rett Syndrome News
After expatriation of a partnership agreement with Astellas, Taysha Gene Therapies regained full rights to TSHA-102, its experimental gene therapy being developed to treat Rett syndrome. “We are thrilled to regain full global rights to our lead TSHA-102 Rett syndrome program, which enables full strategic flexibility and optionality as we continue to advance the program […] The post Taysha regains full rights to TSHA-102 gene therapy for Rett appeared first on Rett Syndrome News.| Rett Syndrome News – The Web's Daily Resource for Rett Syndrome News
NGN-401, a gene therapy treatment people with Rett syndrome, has shown positive results from an ongoing Phase 1/2 trial.| Rett Syndrome News
A gene therapy showing potential to restore lost developmental milestones in people living with Rett syndrome has earned breakthrough therapy status from the U.S. Food and Drug Administration (FDA). The experimental therapy, TSHA-102, is being developed by Taysha Gene Therapies. A breakthrough therapy designation is intended to speed the development and review of important new treatments for […] The post FDA grants breakthrough status to Rett syndrome treatment appeared first on Rett Synd...| Rett Syndrome News – The Web's Daily Resource for Rett Syndrome News
October is Rett Syndrome Awareness Month, and supporters are going purple to bring attention to the rare genetic condition. “There’s no one right way to raise awareness,” the International Rett Syndrome Foundation (IRSF) says on its website. “Whether you’re posting on social media, sharing your story, or just starting a conversation, you’re helping others understand what […] The post Rett community goes purple in October for awareness month appeared first on Rett Syndrome News.| Rett Syndrome News – The Web's Daily Resource for Rett Syndrome News
Lab study findings on problems caused by MECP2 gene mutations in Rett syndrome may help scientists to better understand the rare disease.| Rett Syndrome News
One year of daily Daybue (trofinetide) treatment led to improvements in behaviors such as nonverbal communication, alertness, and social interaction and connectedness among children and adults with Rett syndrome. That’s according to published interim data from Acadia Pharmaceuticals‘ Phase 4 LOTUS study that assessed the safety and effectiveness of the approved oral therapy in 227 […] The post Daybue shows real-world benefits for Rett syndrome patients: Study appeared first on Rett Synd...| Rett Syndrome News – The Web's Daily Resource for Rett Syndrome News
Add-on treatment with oral cannabidiol, known as CBD, helped lower seizure frequency in two-thirds of children with Rett in an Italian study.| Rett Syndrome News
Reduced production of orexin, a signaling molecule, is associated with problems in sleep-wake cycles in Rett syndrome mice, a study found.| Rett Syndrome News
Andrea Lobo is a science writer for Rett Syndrome News with a PhD in cell biology/neurosciences. She covers the latest news and information on a variety of Rett syndrome topics.| Rett Syndrome News
Marisa Wexler is a senior science writer for Rett Syndrome News with an MS in cellular and molecular pathology. She covers the latest news and information on a variety of Rett syndrome topics.| Rett Syndrome News
Category archive page for News.| Rett Syndrome News